Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Imugene Limited ( (AU:IMU) ) has shared an update.
Imugene Limited has announced a security consolidation, impacting various options and warrants with expiration dates ranging from 2026 to 2030. This reorganization, effective from July 2025, aims to streamline the company’s capital structure, potentially enhancing its market positioning and operational efficiency.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited operates in the biotechnology industry, focusing on the development of innovative immunotherapies for cancer treatment. The company is known for its pipeline of products aimed at harnessing the immune system to fight cancer, with a market focus on enhancing the efficacy of existing cancer treatments.
Average Trading Volume: 23,971,997
Technical Sentiment Signal: Sell
Current Market Cap: A$126.9M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.